HONEYWELL BEGINS PRODUCTION OF NEAR ZERO GLOBAL WARMING POTENTIAL MEDICAL PROPELLER
Honeywell Solstice® Air (HFO-1234ze(E) cGMP) for use in new generation respiratory inhalers from Astra Zeneca
MORRIS PLAINS, NJ, October 6, 2022 /PRNewswire/ — Honeywell (Nasdaq: HON) today announced the opening of a facility in Baton Rouge, The.which is the company’s first large-scale manufacturing site for Solstice® Air (HFO-1234ze(E) cGMP), a near-zero Global Warming Potential (GWP) medical propellant for use in respiratory inhalers.
Solstice Air is a non-flammable, near-zero GWP, non-ozone depleting, and volatile organic compound (VOC) free propellant (per US EPA and CARB) in clinical development today for pressurized metered dose inhalers ( pMDI). AstraZeneca (LON: AZN), a global leader in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), is working to integrate Honeywell’s Solstice Air technology, which is in the pipeline. rated for use as a medical propellant and has up to 99.9% less GWP than propellants currently used in inhaled respiratory medications. AstraZeneca awaits their triple therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) to be the first drug to transition to the next generation propellant, subject to regulatory approval, followed by the rest of their pMDI portfolio.
“AstraZeneca’s business partnership with Honeywell is a great example of a true commitment to advancing innovation in healthcare to improve outcomes for both patients and the planet,” said Pablo Panella, senior vice president, Global Respiratory & Immunology, AstraZeneca. “Through close collaboration and extensive knowledge sharing between our two companies, we are committed to bringing patients the next generation of inhaled medications with near-zero GWP propellant. Honeywell’s ability to scale production of Solstice Air at its new manufacturing site will help enable us to move quickly on this ambition once regulatory approval is obtained.”
“Honeywell is committed to supporting our customers’ environmental transformations with out-of-the-box solutions,” said Ken West, president of Honeywell Advanced Materials. “The opening of this factory in Red Stick is Honeywell’s first site to produce a medical-grade propellant and our continued collaboration with AstraZeneca provides a critical moment to highlight how Honeywell’s Solstice technology plays an important role in helping the pharmaceutical industry achieve its goals of sustainability while supporting essential care for respiratory patients worldwide. »
Honeywell has invested more than a billion dollars in research, development and new capabilities for its Solstice technology, having anticipated the need for low-GWP solutions to combat climate change more than a decade ago. The Solstice product line, which helps customers reduce greenhouse gas emissions and improve energy efficiency without sacrificing end-product performance, includes refrigerants for supermarkets, air conditioning for cars and trucks , blowing agents for insulation, propellants for personal and household care and solvents for cleaning solutions.
The use of Honeywell Solstice technology has prevented the potential release of the equivalent of more than 295 million metric tons of carbon dioxide into the atmosphere so far, equivalent to the carbon emissions of nearly 688 million barrels of oil.
Honeywell is committed to achieve carbon neutrality in its operations and facilities by 2035 and recently announced a new series of commitments that advance its Sustainable Development Goals, including committing to science-based target setting with the Science Based Targets initiative (SBTi) that will include Scope 3 emissions and participation in the U.S. Department of Energy’s Better Climate Challenge . The company also supports the Paris Climate Agreement. These efforts build on the company’s track record of drastically reducing the greenhouse gas intensity of its operations and facilities, as well as its decades of innovation to help its customers achieve their environmental and social objectives. In 2021, approximately 60% of Honeywell’s new product launches investment in research and development aimed for products that improve environmental and social outcomes for customers.
For more information on Solstice Air (HFO-1234ze(E) cGMP), its applications and impact, visit: https://sustainability.honeywell.com/us/en
For more information on sustainability at AstraZeneca, visit: https://www.astrazeneca.com/Sustainability.html
Honeywell (www.honeywell.com) provides industry-specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help planes, buildings, manufacturing plants, supply chains and workers become more connected to make our world smarter, safer and more sustainable. For more news and information about Honeywell, please visit www.honeywell.com/newsroom.